EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Severity of Hearing Loss in Cancer Survivors Children After Chemotherapy

Arifa saif, Ayesha Badar, Daniel Akhtar, Muhammad Abdullah, Eshah Nadeem, Tehreem Tariq

Link Medical Journal · 2026

DOI: 10.61919/arcmx655 ↗
AbstractBibliografische Angaben

Abstract

Background: Hearing impairment is a recognized complication among childhood cancer survivors exposed to potentially ototoxic chemotherapy. Early identification of auditory dysfunction is important for communication, educational participation, and quality of life. Objective: To determine the frequency, type, and severity of hearing loss among pediatric cancer survivors following chemotherapy. Methods: A descriptive cross-sectional study was conducted at Jinnah Hospital, Lahore, Pakistan. A total of 162 children aged 6–15 years with a history of chemotherapy were recruited through purposive sampling. Demographic and treatment-related information was collected using a structured questionnaire. Otoscopy and pure-tone audiometry were performed to assess hearing status. Data were analyzed using SPSS version 25, and categorical variables were summarized using frequencies and percentages. Results: Of 162 participants, 98 (60.5%) were male and 64 (39.5%) were female. Hearing impairment was recorded in 145 children (89.5%). Sensorineural hearing loss was the most common type (65.4%), followed by mixed hearing loss (24.1%). Moderate-to-severe hearing loss was the predominant severity category (58.0%), followed by mild-to-moderate (25.9%) and severe-to-profound hearing loss (5.6%). Hearing difficulties in noisy environments were reported by 59.9% of participants, while only 4.3% used hearing assistive devices. Conclusion: A substantial proportion of pediatric cancer survivors in this clinical sample demonstrated hearing impairment, predominantly sensorineural and moderate-to-severe in nature. The findings support routine audiological surveillance and timely rehabilitation following cancer treatment. Causal relationships could not be established because of the cross-sectional design.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →